As healthcare shifts from “volume to value” we are seeing a global trend of shifting medicines
and technology pricing towards a value based paradigm. This comprehensive symposium will
cover off “value based agreements” and innovative financial contracts between pharmaceutical
manufactures and payers. We will go through VBA nomenclature through to design and
architecture of value based agreements across different drug types, therapy areas and payer
archetypes. There will be case presentations of successful VBA from across the globe, focusing
on US & EU markets, with market analysis and deconstruction of these agreements. There will be
a focus on “why do a VBA” and key drivers from manufacturers and payers to ensure success for
all parties for access and reimbursement with innovative contracting mechanisms. Finally, we will
explore how pharmaceutical manufacturers are undertaking organizational change as they move
up the VBA adoption curve and improve resource and x-functional team working. To support
successful deployment and scalability of VBA’s across in market and pipeline portfolio products.

Who Should Attend?

Industry:
Biotechnology,Medical Devices, Medical Practice, Pharmaceuticals
Positions:
• Market access
• Value Access Strategy
• Payer Evidence
• HEOR
• Account Directors
• Pricing and reimbursement

Omar Ali